ChemoFx May Improve Survival of Ovarian Cancer Patients
May 29, 2008
Results provided by the laboratory test ChemoFx(R) may improve survival among patients with ovarian cancer. These findings were published in the Journal of Clinical Oncology and will be presented at the upcoming 2008 annual meeting of the American Society of Clinical Oncology. Ovarian cancer is the most deadly gynecologic cancer in the United States. The study included 206 women with Stages II-IV ovarian cancer who were tested with ChemoFx and received at least one course of chemotherapy between 1997 and 2003. Sean McDonald, CEO of Precision Therapeutics, said "The goal of ChemoFx is to empower patients and physicians with additional diagnostic information to help determine the most appropriate course of therapy for each individual patient." Read more about ChemoFx at www.precisiontherapeutics.com.
« TOA Named to Visionaries Quandrant in 2008 Field Service Management Magic Quandrant | | AlphaLab Incubator Opens in Pittsburgh »
